Tag: Sanofi

October 7, 2015 Off

Sanofi: New Analysis on Relapsing Multiple Sclerosis

By Dino Mustafić

Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).